300+ investors in your industry, stage, and region Get
Any industry
Video Games
Hospitality
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
Big Data
CleanTech
Email
Artificial Intelligence
Social Impact
SaaS
Energy
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Retail
Oil and Gas
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
Facebook
B2B
Blockchain
Social Network
Medical Device
Education
Wellness
Sports
Automotive
eSports
Legal
Biotechnology
Software
Renewable Energy
Crowdfunding
Recruiting
Web3
Medical
Theatre
Venture Capital
Social
Infrastructure
Beauty
Fashion
Climate
LGBT
Cannabis
Celebrity
Life Science
Food and Beverage
Publishing
Mobile Apps
Wine and Spirits
Music
Manufacturing
FinTech
Finance
Digital Media
Social Media
Financial Services
Art
Franchise
Non Profit
Internet
Mobile Advertising
Android
Proptech
Impact
Real Estate
Sustainability
Hardware
Sporting Goods
Biotech
Transportation
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
South Korea
Japan
Burkina Faso
Africa
Singapore
Gibraltar
Egypt
Taiwan
Zimbabwe
Tunisia
Sweden
Oceania
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Haiti
Kyrgyzstan
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Brazil
LATAM
Puerto Rico
Oman
Poland
Cameroon
Guernsey
China
Colombia
Armenia
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Morocco
Australia
Saudi Arabia
Sri Lanka
Jamaica
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Seychelles
Moldova
Botswana
Paraguay
Canada
South Africa
France
Denmark
Georgia
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
El Salvador
Senegal
Tanzania
India
Germany
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Europe
Qatar
Angola
Cyprus
Argentina
Bangladesh
Barbados
Belgium
Jordan
Ethiopia
Austria
Azerbaijan
Bulgaria
Ecuador
Faroe Islands
Jersey
Bahrain
Estonia
Bahamas
Ireland
Bolivia
Belize
Algeria
Italy
Belarus
Finland
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
GISEV Family Office, VC Fund

GISEV Family Office

VC Fund

Lugano, Switzerland

GISEV Family Office is a investment firm.

Total investments:
8
Last investment:
Lead investor:
25%

Last updated:

Industries GISEV Family Office invests in

Health CareBiotechnologyWellnessTherapeuticsPersonal Health

Stages GISEV Family Office invests in

Series ASeedPre-SeedSeries BSeries C

Countries GISEV Family Office invests in

United StatesArgentinaUnited Kingdom

Round sizes

Series A $11M–$40M

Round size

Series A
$11M–$40M

Investment Focus

Industry

  • Health Care 6 (75%)
  • Biotechnology 4 (50%)
  • Wellness 3 (38%)
  • Therapeutics 3 (38%)
  • Personal Health 2 (25%)
See all 14 industries →

Stage

  • Series A 3 (38%)
  • Seed 1 (13%)
  • Pre-Seed 1 (13%)
  • Series B 1 (13%)
  • Series C 1 (13%)
See all 6 stages →

Country

  • United States 6 (75%)
  • Argentina 1 (13%)
  • United Kingdom 1 (13%)

Investments

CompanyDescriptionRoundLinks
Bionaut Labs revolutionizes the treatment of central nervous system disorders with its precision medicine treatment modality. By creating a new medical modality of remote-controlled micro-robots called Bionauts, the company can transform the way the biopharmaceutical industry develops treatments, allowing them to engineer the therapeutic index forefficacy and maintain safety.Bionaut Labs is focused on helping patients suffering from debilitating brain diseases who have few available treatment options. The anatomical targeting capabilities of the Bionaut platform make new therapeutics technologies such as gene therapy, CRISPR-Cas9, and oncolytic viruses viable in challenging clinical settings. $43.2M / Series B / Nov 28, 2022
Revea is a us-based one-of-its-kind precision skincare company. $6M / Seed / Apr 21, 2022
Syocin Biotech is developing a synthetic biology platform for the redesign of natural existing biomolecules to precisely target plant bacterial pathogens that threaten world food availability. $450K / Pre-Seed / Dec 30, 2021
Seed Health is a microbial company that specializes in therapeutics, consumer health innovations, and environmental solutions. The company focuses on breakthrough discoveries in microbial sciences across a pipeline of novel therapeutics. It was founded by Ara Katz and Raja Dhir in 2017 and is headquartered in Venice, California. $40M / Series A / Apr 21, 2021
Voy Voy
Manual is a men’s health and well-being startup offering a suite of diagnostic tools and blood tests to offer data-driven health solutions. The company provides men with easy access to advice, free medical support, and the treatment choices they need to help them make proactive decisions about their wellbeing.Manual was founded in 2018 and isheadquartered in London, UK. $30.2M / Series A / Mar 30, 2021
Solarea Bio is a biotech company that develops microbial therapeutics aimed to treat indications derived from chronic inflammation to aid human health.It specializes in the research and development of therapeutics that are derived from natural sources and are aimed to treat indications derived from chronic inflammation, enabling hospitals toprovide medicinal drugs for improved quality of life. The company generates a large database of the complete genomic sequences of microbes derived from healthy foods. Using computational approaches, Solarea generates synergistic combinations of bacteria, fungi, and prebiotic fibers with powerful anti-inflammatory capabilities to address specific chronic conditions that afflict large numbers of people. These have been validated in-vitro and in-vivo in preclinical mouse models. Its first application aims to aid in the dietary management of the metabolic processes that cause osteopenia and osteoporosis in postmenopausal women. This provides a nature-based solution to improving women’s health and well-being.The Cambridge, Massachusetts-based company was established in 2017 by Eric Schott, Gerardo Toledo, and Jillian DeWalt. $11.2M / Series A / Oct 19, 2020
Symbiome offers skincare as nature intended solution which is scientifically and intentionally formulated using ancestral ingredients. It was founded in 2017 and is headquartered in San Francisco, California. $15M / Venture - Series Unknown / Sep 14, 2020
Elysium Health offers health products built with science such as dietary supplements and anti-aging drugs. It seeks to solve challenges in health with science, to help people live healthier and longer lives. It works directly with the scientists, clinicians, and health professionals around the world to identify and develop the natural compounds.Its product is a proprietary formulation of two ingredients designed to support long-term well-being at the cellular level. $40M / Series C / Dec 23, 2019

Co-Investors

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
Video Games
Hospitality
EdTech
Restaurants
Google
Construction
Photography
Cryptocurrency
Clean Energy
Big Data
CleanTech
Email
Artificial Intelligence
Social Impact
SaaS
Energy
Mobile
Consumer
Health Care
Enterprise Software
Local
Platforms
Travel
InsurTech
Retail
Oil and Gas
Film
Payments
Marketplace
Organic Food
Fitness
Machine Learning
Agriculture (AgTech)
Gaming
Facebook
B2B
Blockchain
Social Network
Medical Device
Education
Wellness
Sports
Automotive
eSports
Legal
Biotechnology
Software
Renewable Energy
Crowdfunding
Recruiting
Web3
Medical
Theatre
Venture Capital
Social
Infrastructure
Beauty
Fashion
Climate
LGBT
Cannabis
Celebrity
Life Science
Food and Beverage
Publishing
Mobile Apps
Wine and Spirits
Music
Manufacturing
FinTech
Finance
Digital Media
Social Media
Financial Services
Art
Franchise
Non Profit
Internet
Mobile Advertising
Android
Proptech
Impact
Real Estate
Sustainability
Hardware
Sporting Goods
Biotech
Transportation
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
United Kingdom
Thailand
United Arab Emirates
Andorra
Benin
South Korea
Japan
Burkina Faso
Africa
Singapore
Gibraltar
Egypt
Taiwan
Zimbabwe
Tunisia
Sweden
Oceania
Hong Kong
Nigeria
Togo
Croatia
Iran
Guinea
Haiti
Kyrgyzstan
Norway
Lesotho
Isle of Man
Liberia
Malawi
Nepal
Mexico
Madagascar
Russian Federation
Sudan
Pakistan
Tajikistan
Zambia
Romania
Brazil
LATAM
Puerto Rico
Oman
Poland
Cameroon
Guernsey
China
Colombia
Armenia
Costa Rica
Czech Republic
Kenya
Kuwait
Marshall Islands
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
New Zealand
Morocco
Australia
Saudi Arabia
Sri Lanka
Jamaica
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Turkey
Uruguay
Seychelles
Moldova
Botswana
Paraguay
Canada
South Africa
France
Denmark
Georgia
Ghana
Iraq
Latvia
Mali
Malaysia
Philippines
Portugal
Rwanda
Sierra Leone
El Salvador
Senegal
Tanzania
India
Germany
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Europe
Qatar
Angola
Cyprus
Argentina
Bangladesh
Barbados
Belgium
Jordan
Ethiopia
Austria
Azerbaijan
Bulgaria
Ecuador
Faroe Islands
Jersey
Bahrain
Estonia
Bahamas
Ireland
Bolivia
Belize
Algeria
Italy
Belarus
Finland
Hungary
Grenada
Israel
Lithuania
Honduras
Iceland
Cambodia
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Chile
Vietnam
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does GISEV Family Office invest in?

GISEV Family Office invests primarily in Health Care, Biotechnology and Wellness startups, most often at Series A and Seed stage. Most of the 8 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What round sizes does GISEV Family Office invest in?

GISEV Family Office typically joins rounds of $11M–$40M at Series A. These are whole funding-round sizes, not GISEV Family Office's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds GISEV Family Office took part in.

When did GISEV Family Office last invest?

The most recent investment recorded for GISEV Family Office closed in Nov 2022. Shizune tracks 8 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
GISEV Family Office GISEV Family Office Find emails